

Corporate presentation

Dr. Jérôme Gabard PhD.
CEO

Pherecydes Pharma

1. Bacteriophages
2. R&D
3. Pherecydes Pharma
4. Questions

1. Bacteriophages

- Bacteriophages





Bacteriophages

1. Phages

- Bacteria natural predators
- Discovered in 1917
- High bacterial specificity



Félix d'Hérelle




2. Research & Developement

- Global view
- TAPE
- Ab-Accus
- RiPh
- Potential applications
- Anti infective strategy



R & D

2. Global view




R & D

2. TAPE

- Targeted Accelerated Protein Evolution
 - Patented *in vitro* process
 - Random mutations in any selected regions
 - Conserves intact coding domains
- Defined preliminary requirements
 - Know gene sequence
 - Set densities of required mutations



A variety of applications



Therapeutic antibody affinity increase

Bioconversion/biocatalysis process optimization

Industrial enzymatic reaction enhancement



Research & development

2. Ab-ACCUS

- Rapid & efficient production of T4 phage banks
 - Proprietary recombination process
 - Several proteins are manipulated at once
 - Each individual differs from all others for at least one component of its host-targeting system
 - Number of variants nears infinity
- New host-ranges
 - TAPE + Ab-ACCUS = millions of phage variants
 - Modified gram- bacteria host range profiles
 - Capacity to infect bacterial serotypes as well as different bacterial species


Research & development

2. RiPh

- RiPh: Reversible Inhibition of Phages
 - Patent submitted and pending
- A process for stopping phage replication in host, once DNA is injected into bacteria
- A reversible system to restart phage DNA replication and lytic cycle, as needed

R & D

2. Potential applications




R & D

2. Anti infective phage strategy

Host recognition is based on tail fibers.


- Modify protein tail fibers
- Create huge diversities of tail proteins
- Design banks of phages that recognize:
 - Different bacterial strains
 - Diverse bacterial species
- Select phage variants to control:
 - Antibiotic multi resistant bacterial strains
 - Phage resistant bacteria
 - Emerging bacteria



A process to fight resistance as with influenza vaccine.

3. Pherecydes Pharma

- Shareholders
- Management
- Contacts



3. Shareholders

- Venture capital
 - Fond Sécurité and Financière de Brienne
 - Investment € 1.15 million: first round
 - ACE Management
 - 7 investment funds
 - Managing € 300 million in capital
 - For industrial and financial leaders



FOUNDED BY INDUSTRY
ENTREPRENEURS
AND TRUSTED BY
PRIVATE EQUITY


- Private company
 - BioModeling Systems S.A.S Company
 - Manuel Géa and François Iris
 - Predictive integrated biology

Discover ed both genuine
concepts behind TAPE &
Ab-Accus patents

Pherecydes Pharma

3. Management

- CEO: Dr. Jérôme Gabard
 - The Marketch Group: Life Sciences Dir.
 - Euroclide SA: CEO
 - Qualicon: Business Developer
 - Du Pont De Nemours: R&D Project Manager
- Head of R&D: Dr. Flavie Pouillot
 - Institut Pasteur in Paris
 - Protection against *Yersinia pestis*
 - Pathogenicity mechanisms.
 - PhD in microbiology and molecular biology
 - Institut Pasteur
 - University Pierre & Marie-Curie - Paris



Pherecydes Pharma

3. Contacts



- Address

Pherecydes Pharma
Biocitech
102 avenue Gaston Roussel
93230 Romainville - France

- Contacts

Business development: Jérôme GABARD

Jerome.gabard@pherecydes-pharma.com

Investors : Delphine DINARD (ACE Management)

del@acemanagement.fr

R&D: Flavie POUILLOT

flavie.pouillot@pherecydes-pharma.com